Subarachnoid Hemorrhage, Aneurysmal
Conditions
Brief summary
Aneurysmal subarachnoid hemorrhage (aSAH) can cause a severe headache (HA) that is famously treatment-resistant. Current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and delayed cerebral ischemia. This study will gather the initial evidence of whether the pterygopalatine fossa (PPF) regional anesthesia nerve block can treat aSAH-related HA and reduce opioid consumption in patients with aSAH.
Interventions
PROCEDUREPtergyopalatine Fossa Block
Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
Sponsors
University of Texas Southwestern Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aneurysmal subarachnoid hemorrhage with secured aneurysm * Age greater than or equal to 18 years * Able to communicate pain level
Exclusion criteria
* Documented allergy to local anesthetics (e.g. bupivicaine) * Patients with unsecured aneurysms * Patients who are unable to communicate pain level (e.g. sedation/mechanical ventilation/delirium, etc) * Medical treatment for vasospasm including blood pressure/inotropic augmentation * Angiographic treatment for vasospasm within 48 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Opioid consumption | 3 days | — |
| Pain Rating Scale | 3 days | Scale of 1-10, 1 being lowest possible pain, 10 being highest possible pain |
Countries
United States
Outcome results
None listed